Executive Summary
Padagis US LLC seeks IPR cancellation of Neurelis' 8,895,546 patent covering intranasal benzodiazepine solutions, arguing obviousness over Gwozdz and Meezan and invoking collateral estoppel from a prior IPR.
Related Cases
MWE Investments, LLC et al.vsChampion Power Equipment, Inc.
MWE Investments and Champion Power Equipment settled their IPR dispute over U.S. Patent 11,530,654 and jointly requested that the settlement agreement be kept confidential, while MWE moved to withdraw from the proceeding.
EP Family Corp.vsOffice Kick Inc.
EP Family Corp. and Office Kick, Inc. settled their dispute and jointly moved to terminate the IPR before any institution, resulting in a confidential settlement and dismissal of the proceedings.
Google LLCvs--
The PTAB denied Google's attempt to file a second IPR against PROXENSE's patent because the Board had already instituted an earlier review.
AMAZON.COM, INC. et al.vsNokia Technologies Oy
Amazon and Nokia settled their IPR dispute over U.S. Patent 6,856,701 B2. The Board granted a joint motion to terminate the proceeding and partially approved confidentiality for the settlement documents.
Google LLC et al.vsART RESEARCH AND TECHNOLOGY, LLC
Google has filed an IPR petition seeking cancellation of claims 1 and 5‑11 of ART Research’s ’442 patent covering video‑annotation interfaces, alleging obviousness over multiple prior‑art references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.